Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2022

14.04.2022 | review

Highlights ESMO 2021—lung cancer

verfasst von: Dr. Markus Rauter

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The following three abstracts presented at EESMO 2021 highlight three different areas of therapeutic strategies for non small cell lung cancer. First, neoadjuvant Atezolizumab managed to show a superior DFS compared to best supportive care in completely resected NSCLC stage II–IIIA. Second, Cemiplimab combined with chemotherapy reached the primary endpoint of OS compared to chemo alone in advanced stage IIIB/C & stage IV NSCLC patients. Third, the BEVERLY trial showed that the combination of Erlotinib with Bevacizumab in advanced EGFR-mutated NSCLC prooved to be superior to Erlotinib monotherapy in the current/former smoker subgroup, suggesting that this subgroup represents a differnt tumor biology with sprecial therapeutic needs.
Literatur
1.
3.
Zurück zum Zitat Altorki N, Felip E, Zhou C, et al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. In: International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer; September 8–14, 2021; virtual. Abstract PL02.05. Altorki N, Felip E, Zhou C, et al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. In: International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer; September 8–14, 2021; virtual. Abstract PL02.05.
4.
Zurück zum Zitat Zhou C, et al. IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Proffered Paper session 1; 2O – IMpower010; December 9th, 2021. Annals of Oncology 2021;32(suppl_7):S1373–91. https://​doi.​org/​10.​1016/​annonc/​annonc784. CrossRef Zhou C, et al. IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Proffered Paper session 1; 2O – IMpower010; December 9th, 2021. Annals of Oncology 2021;32(suppl_7):S1373–91. https://​doi.​org/​10.​1016/​annonc/​annonc784. CrossRef
5.
Zurück zum Zitat Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef
6.
Zurück zum Zitat Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef
7.
Zurück zum Zitat Piccirillo MC. Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. In: Proffered Paper session – NSCLC, metastatic 1; September 18th, 2020. Presentation 12070. Annals of Oncology 2021;32(suppl_5):S949–1039. https://​doi.​org/​10.​1016/​annonc/​annonc729. CrossRef Piccirillo MC. Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. In: Proffered Paper session – NSCLC, metastatic 1; September 18th, 2020. Presentation 12070. Annals of Oncology 2021;32(suppl_5):S949–1039. https://​doi.​org/​10.​1016/​annonc/​annonc729. CrossRef
8.
Zurück zum Zitat Saito H, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. LancetOncolol. 2019;20(5):625–35. Saito H, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. LancetOncolol. 2019;20(5):625–35.
9.
Zurück zum Zitat Maemondo M, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. JCO Clin Cancer Inform. 2020;38(15suppl):9506. Maemondo M, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. JCO Clin Cancer Inform. 2020;38(15suppl):9506.
10.
Zurück zum Zitat Soo R. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. In: Virtual Plenary Debate; September 17th, 2021; Abstract VP3_2021. Soo R. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. In: Virtual Plenary Debate; September 17th, 2021; Abstract VP3_2021.
11.
Zurück zum Zitat Kenmotsu H, et al. Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study. In: Proffered Paper session – NSCLC, metastatic; September 18th, 2021. Presentation LBA44. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef Kenmotsu H, et al. Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study. In: Proffered Paper session – NSCLC, metastatic; September 18th, 2021. Presentation LBA44. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741. CrossRef
Metadaten
Titel
Highlights ESMO 2021—lung cancer
verfasst von
Dr. Markus Rauter
Publikationsdatum
14.04.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00801-0